Nicolas Girard

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. ncbi Thymic epithelial tumours: from basic principles to individualised treatment strategies
    Nicolas Girard
    Dept of Respiratory Medicine, National Expert Centre for Thymic Malignancies, Reference Centre for Orphan Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France
    Eur Respir Rev 22:75-87. 2013
  2. ncbi Other signalization targets
    Nicolas Girard
    Department of Respiratory Medicine, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France
    Target Oncol 8:69-77. 2013
  3. ncbi Chemotherapy and targeted agents for thymic malignancies
    Nicolas Girard
    Department of Respiratory Medicine, Pilot Unit for the Management of Rare Intrathoracic Tumors, National Expert Center for Thymic Malignancies, Louis Pradel Hospital, Hospices Civils de Lyon, avenue Doyen Lepine, Lyon, France
    Expert Rev Anticancer Ther 12:685-95. 2012
  4. ncbi Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
    N Girard
    Service de Pneumologie U80, Hopital Louis Pradel, 28 Avenue Doyen Lepine, 69677 Lyon, Bron Cedex, France
    Eur Respir J 39:366-72. 2012
  5. ncbi Thymic tumors: relevant molecular data in the clinic
    Nicolas Girard
    Department of Respiratory Medicine, Reference Center for Rare Pulmonary Diseases, Pilot Unit for the Management of Rare Intra Thoracic Tumors, Hospices Civils de Lyon, Lyon, France
    J Thorac Oncol 5:S291-5. 2010
  6. ncbi [Confidentiality in medical practice: tell no one]
    Sébastien Couraud
    Service de Pneumologie, Hopital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
    Bull Cancer 96:791-5. 2009
  7. ncbi Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
    Nicolas Girard
    Department of Radiotherapy Oncology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, Lyon, France
    Lung Cancer 69:86-93. 2010
  8. ncbi [A difficult end of life]
    Julie Traclet
    Service de Pneumologie, Hopital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
    Bull Cancer 96:805-9. 2009
  9. ncbi [Stereotactic radiotherapy and radiofrequency ablation for early-stage lung cancer]
    Fabrice Piegay
    Université Lyon I, Lyon, France
    Bull Cancer 99:1077-81. 2012
  10. ncbi Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial
    Nicolas Girard
    Department of Radiotherapy Oncology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
    Int J Radiat Oncol Biol Phys 77:1426-32. 2010

Collaborators

Detail Information

Publications24

  1. ncbi Thymic epithelial tumours: from basic principles to individualised treatment strategies
    Nicolas Girard
    Dept of Respiratory Medicine, National Expert Centre for Thymic Malignancies, Reference Centre for Orphan Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France
    Eur Respir Rev 22:75-87. 2013
    ....
  2. ncbi Other signalization targets
    Nicolas Girard
    Department of Respiratory Medicine, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France
    Target Oncol 8:69-77. 2013
    ..From bench to bedside, personalized medicine represents a major revolution in the treatment of lung cancer...
  3. ncbi Chemotherapy and targeted agents for thymic malignancies
    Nicolas Girard
    Department of Respiratory Medicine, Pilot Unit for the Management of Rare Intrathoracic Tumors, National Expert Center for Thymic Malignancies, Louis Pradel Hospital, Hospices Civils de Lyon, avenue Doyen Lepine, Lyon, France
    Expert Rev Anticancer Ther 12:685-95. 2012
    ..More recently, the molecular characterization of thymoma and thymic carcinoma led to the identification of potentially druggable targets, laying the foundations to implement personalized medicine for patients...
  4. ncbi Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
    N Girard
    Service de Pneumologie U80, Hopital Louis Pradel, 28 Avenue Doyen Lepine, 69677 Lyon, Bron Cedex, France
    Eur Respir J 39:366-72. 2012
    ....
  5. ncbi Thymic tumors: relevant molecular data in the clinic
    Nicolas Girard
    Department of Respiratory Medicine, Reference Center for Rare Pulmonary Diseases, Pilot Unit for the Management of Rare Intra Thoracic Tumors, Hospices Civils de Lyon, Lyon, France
    J Thorac Oncol 5:S291-5. 2010
    ..Insights have been made following anecdotal clinical responses to targeted therapies, and large-scale genomic analyses have been conducted...
  6. ncbi [Confidentiality in medical practice: tell no one]
    Sébastien Couraud
    Service de Pneumologie, Hopital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
    Bull Cancer 96:791-5. 2009
    ....
  7. ncbi Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
    Nicolas Girard
    Department of Radiotherapy Oncology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, Lyon, France
    Lung Cancer 69:86-93. 2010
    ..Induction chemoradiotherapy with modern treatment regimens is highly feasible and may show promises in the current and future developments of multimodal therapeutic strategies in locally advanced NSCLC...
  8. ncbi [A difficult end of life]
    Julie Traclet
    Service de Pneumologie, Hopital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
    Bull Cancer 96:805-9. 2009
    ..This observation asks the question of the medical certificates: how and when write them, which are obligatories? Moreover, how should a patient or his beneficiaries obtain medical records?..
  9. ncbi [Stereotactic radiotherapy and radiofrequency ablation for early-stage lung cancer]
    Fabrice Piegay
    Université Lyon I, Lyon, France
    Bull Cancer 99:1077-81. 2012
    ..Overall, from a technical concept to the availability of specific treatment devices and the publication of clinical results, stereotactic radiotherapy and radiofrequency ablation are paradigms of implementation in thoracic oncology...
  10. ncbi Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial
    Nicolas Girard
    Department of Radiotherapy Oncology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
    Int J Radiat Oncol Biol Phys 77:1426-32. 2010
    ..To accurately determine the maximal tolerated dose, feasibility, and antitumor activity of concurrent chemoradiotherapy including twice-weekly gemcitabine in patients with unresectable pancreatic adenocarcinoma...
  11. ncbi Professional exposure to goats increases the risk of pneumonic-type lung adenocarcinoma: results of the IFCT-0504-Epidemio study
    Delphine Lutringer-Magnin
    Hospices Civils de Lyon, Lyon, France
    PLoS ONE 7:e37889. 2012
    ..043), as compared to other subtypes of lung cancer. This case-control suggests a link between professional exposure to goats and P-ADC, and prompts for further epidemiological evaluation of potential environmental risk factors for P-ADC...
  12. ncbi Highlights of the 2nd European Lung Cancer Conference
    Nicolas Girard
    Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France UMR 754, Claude Bernard University, Lyon, France
    Expert Rev Anticancer Ther 10:1023-5. 2010
    ....
  13. ncbi Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial
    Francoise Mornex
    département de radiothérapie oncologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon France
    Int J Radiat Oncol Biol Phys 65:1471-8. 2006
    ..Neoadjuvant chemoradiotherapy might offer potential benefits regarding local and systemic control and survival. This multi-institutional Phase II trial explored the feasibility of preoperative chemoradiation in this situation...
  14. ncbi [Chemoradiation therapy: a model for treatment optimization in oncology]
    Francoise Mornex
    département de radiothérapie oncologie, Centre Hospitalier Lyon Sud, Lyon
    Bull Cancer 93:751-60. 2006
    ..Lung cancer represents a model of organization of multimodal therapeutic algorithms, the ultimate aim being the therapeutic optimization of the most frequent cancer...
  15. ncbi Thymoma: a focus on current therapeutic management
    Nicolas Girard
    Department of Radiotherapy, Lyon Sud Hospital, Universite de Lyon, Lyon, France
    J Thorac Oncol 4:119-26. 2009
    ....
  16. ncbi [Radiotherapy for non-small cell lung cancer]
    Nicolas Girard
    Service de Pneumologie, Hopital Louis Pradel, Hospices Civils de Lyon, Lyon, France
    Rev Prat 59:943-7. 2009
    ....
  17. ncbi Jaagsiekte Sheep Retrovirus (JSRV): from virus to lung cancer in sheep
    Caroline Leroux
    Universite de Lyon 1, INRA, UMR754, Ecole Nationale Veterinaire de Lyon, IFR 128, F 69007, Lyon, France
    Vet Res 38:211-28. 2007
    ..Activation of the PI3K/Akt and MAPK pathways participates in the envelope-induced transformation. Tumour development is associated with telomerase activation. This review will focus on the induction of cancer by JSRV...
  18. ncbi Targeted therapies for thymic malignancies
    Nicolas Girard
    Department of Respiratory Medicine, Pilot Unit for the Management of Rare Intrathoracic Tumors, Louis Pradel Hospital, Lyon 69677, France
    Thorac Surg Clin 21:115-23, viii. 2011
    ..This article reviews current knowledge about the molecular data that define molecular subsets and support the use of targeted therapies in thymic tumors...
  19. ncbi Transsternal transpericardial closure of a postpneumonectomy bronchial fistula in a patient who underwent pneumonectomy because of a war injury
    Nicolas Girard
    Department of Respiratory Medicine, Hopital Louis Pradel, Hospices Civils de Lyon, France
    Gen Thorac Cardiovasc Surg 57:660-3. 2009
    ....
  20. ncbi [A difficult diagnosis]
    Véronique Porot
    Service de Pneumologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
    Bull Cancer 96:785-9. 2009
    ..The non-malignant character of the suspected lesion raise questions about the risks involved, the benefit/risk balance, and the legal risk scopes of the medicosurgical staff as defined in the Cancer programme framework...
  21. ncbi Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial
    Francoise Mornex
    Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Lyon, France
    Int J Radiat Oncol Biol Phys 66:1152-8. 2006
    ..Although conventional radiotherapy has been traditionally regarded as inefficient and toxic for cirrhotic patients, three-dimensional conformal radiotherapy (3DCRT) has provided promising preliminary data for the treatment of HCC...
  22. ncbi Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases
    Nicolas Girard
    Department of Respiratory Medicine, , Hospices Civils de Lyon, Lyon, France
    Lung Cancer 53:51-8. 2006
    ....
  23. ncbi Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment
    Francoise Mornex
    département de radiothérapie oncologie, Centre Hospitalier Lyon Sud, Lyon, France
    Semin Radiat Oncol 15:226-34. 2005
    ..Finally, more efficient novel neoadjuvant approaches are required to address the high metastatic potential of pancreatic cancer. These areas are discussed in depth...
  24. ncbi Standard-fractionated radiotherapy for optic nerve sheath meningioma: visual outcome is predicted by mean eye dose
    Lucie Abouaf
    Neuro Ophthalmology Unit, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Lyon, France
    Int J Radiat Oncol Biol Phys 82:1268-77. 2012
    ..However, radiation-induced toxicity may ultimately jeopardize the functional benefit. The purpose of this study was to identify predictive factors of poor visual outcome in patients receiving radiotherapy for ONSM...